India vs Least Developed Countries (LDCs): Percentage of bloodstream infection due to Escherichia coli resistant
India
77.5%
in 2022
Least Developed Countries (LDCs)
73.5%
in 2022
India rank
4th
Least Developed Countries (LDCs) rank
4th
Percentage of bloodstream infection due to Escherichia coli resistant over time
- India
- Least Developed Countries (LDCs)
How they compare
India currently reports 77.5% against 73.5% in Least Developed Countries (LDCs), a difference of 4.0%.
That makes India's figure about 1.1 times Least Developed Countries (LDCs)'s.
The two have swapped places 2 times across 6 shared years of data; in 2017 it was India ahead.
India ranks 4th and Least Developed Countries (LDCs) ranks 4th of 50 countries.
India has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | India | Least Developed Countries (LDCs) | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 78.2% | 51.7% | 26.6% | India |
| 2020s | 80.6% | 72.7% | 7.9% | India |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher percentage of bloodstream infection due to escherichia coli resistant, India or Least Developed Countries (LDCs)?
- India, at 77.5% against 73.5% in Least Developed Countries (LDCs) as of 2022.
- What is the difference in percentage of bloodstream infection due to escherichia coli resistant between India and Least Developed Countries (LDCs)?
- 4.0%, with India ahead.
- How many years of comparable data are there for India and Least Developed Countries (LDCs)?
- 6 years are reported by both, from 2017 to 2022.
- How do India and Least Developed Countries (LDCs) rank globally for percentage of bloodstream infection due to escherichia coli resistant?
- India ranks 4th and Least Developed Countries (LDCs) ranks 4th of 50 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Percentage of bloodstream infection due to Escherichia coli resistant to 3rd-generation cephalosporin (e.g., ESBL- E. coli) among patients seeking care and whose blood sample is taken and tested (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.